All Companies


Acceleron Pharma Inc [XLRN] US$2,159 MM MCap
Lead ther­a­peu­tic can­di­date in he­ma­tol­o­gy, lus­pa­ter­cept, un­der a glob­al part­n­er­ship with Cel­gene, re­port­ed pos­i­tive Phase 3 ME­DAL­IST and BE­LIEVE trial re­sults, and cont­in­ues to ad­vance mul­ti­ple Ph2 and Ph3 trials for the treat­ment of chron­ic ane­mia in myelodys­plas­tic syn­dromes, be­ta-tha­lassemia, and myelo­fi­bro­sis. [more in­for­ma­tion]
AcelRx Pharmaceuticals, Inc. [ACRX] US$220 MM MCap
Re­cent­ly launched DSU­VIA; rev-gen­er­at­ing in Q1. Plans to re­sub­mit Za­lvi­so NDA in US by YE [more in­for­ma­tion]
Adverum Biotechnologies [ADVM] US$1,013 MM MCap
Oc­u­lar and rare dis­ease gene ther­a­py com­pany. Lead pro­gram, AD­VM-022, cur­rent­ly in a Phase 1 study in wAMD. Pre­clin­i­cal pro­grams in A1AT de­fi­cien­cy and HAE. Col­lab­o­ra­tions in place with Re­generon and Ed­i­tas. [more in­for­ma­tion]
Affibody
Pro­pri­e­tary Af­fi­body® molecules and Al­bu­mod plat­forms. 4 clin­i­cal / late-stage, pro­pri­e­tary pro­grams in­clud­ing pso­ri­a­sis, B-cell au­toim­mune dis­eas­es, & liv­er dis­eas­es. Pipe­line al­so in­cludes Dx imag­ing pro­gram tar­get­ing me­tastat­ic breast can­cer. [more in­for­ma­tion]
Affimed N.V. [AFMD] US$191 MM MCap
Mo­d­u­lar ROCK™plat­form en­abling mul­ti-spe­cif­ic NK / T-cell bi-and tri-spe­cif­ic Abs. Aug 2018 deal w Ge­nen­tech ($96M up­front / $5B po­ten­tial). – AFM13 in P1b (com­bo) in HL and P2a(mono) in CD30+lym­pho­ma [more in­for­ma­tion]
Aileron Therapeutics, Inc. [ALRN] US$16 MM MCap
Clin­i­cal stage on­col­o­gy com­pany con­duct­ing 3 clin­i­cal trials for its lead can­di­date, AL­RN-6924, a first-in-class/best-in-class drug that tar­gets the p53 path­way. AL­RN-6924 is from the Sta­pled pep­tide plat­form and is the on­ly clin­i­cal drug can­di­date that binds equipo­tent­ly to both of the p53 sup­pres­sor pro­teins, MD­MX and MD­M2. [more in­for­ma­tion]
Amarin Corporation [AMRN] US$7,232 MM MCap
Vas­ce­pa: 1st and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA [more in­for­ma­tion]
Antev
Ph3 ready hor­mone ther­a­py com­pany with an in­jectable, long-act­ing GnRH an­ta­g­on­ist for pros­tate can­cer and be­nign pro­stat­ic hy­per­pla­sia. An in­jectable en­ables ex­tend­ed drug ac­tiv­i­ty, which is im­por­tant for in­di­ca­tions with ac­tive oral an­ta­g­on­ists in late-stage de­vel­op­ment and al­so ap­proved agent(s). The safe­ty pro­file looks good with over 415 sub­jects dosed over 805 times. [more in­for­ma­tion]
Apexigen
CD40 ag­on­ist mAb; 170+ pts dosed (mono & com­bi sett­ings). 7 on­go­ing Ph 2s, undis­closed oc­u­lar dis­ease pro­gram in Ph 3. AACR: Ph 1b da­ta (w/Park­er Inst); col­labs w/BMY, MDACC, Yale, et al [more in­for­ma­tion]
Aptorum Group [APM] US$674 MM MCap
Ap­to­rum is a phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to de­vel­op­ing and com­mer­cial­iz­ing a broad range of ther­a­peu­tic and di­ag­nos­tic tech­nolo­gies to tack­le un­met med­i­cal needs. Ap­to­rum is pur­su­ing ther­a­peu­tic and di­ag­nos­tic pro­jects in neu­rol­o­gy, in­fec­tious dis­eas­es, gas­troen­terol­o­gy, on­col­o­gy and other dis­ease ar­eas; [more in­for­ma­tion]
Arcellx
The com­pany raised ven­ture fund­ing from No­vo on Jan­uary 17, 2017. De­vel­op­er of an­ti-tu­mor ther­a­py. The com­pany's an­ti-tu­mor ther­a­py is based on T cell-me­di­at­ed sys­tems that help in de­tect­ing tu­mors in pa­tients. [more in­for­ma­tion]
Ascentage Pharma
Glob­al­ly-fo­cused clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pany de­vel­op­ing first- and best-in-class tar­get­ed ther­a­peu­tics for can­cers, he­p­ati­tis B & age-re­lat­ed dis­eas­es. As­cen­t­age is a lead­er in the de­sign of small molecules ther­a­peu­tics for tar­get­ing pro­tein-pro­tein in­ter­ac­tions in­clud­ing Bcl-2, IAP and MD­M2-p53. The com­pany has 6 prod­uct can­di­dates in clin­i­cal de­vel­op­ment. [more in­for­ma­tion]
AsclepiX Therapeutics
Pri­vate, oph­thal­mol­o­gy fo­cused ear­ly stage com­pany; tech­nol­o­gy out of Johns Hop­kins. Plan­n­ing 4Q19 IND and 1Q20 Ph1/2 ini­ti­a­tion (DME and Wet AMD). AX­T107: nov­el pep­tide in­hibit­ing VEGF and ac­ti­vat­ing Tie2; de­mon­s­trat­ed ef­fi­ca­cy and dura­bil­i­ty in rab­bit and mouse mod­els. [more in­for­ma­tion]
Asklepion Pharmaceuticals
Pri­vate, fo­cused on the de­vel­op­ment of IV Cit­rul­line for rare pe­di­a­tric dis­eas­es. First in­di­ca­tion, the pre­ven­tion of sig­ni­f­i­cant se­que­lae of pe­di­a­tric acute car­diopul­mo­nary by­pass-in­duced lung in­jury, Ph 3 trial is on­go­ing. [more in­for­ma­tion]
Assembly Biosciences, Inc. [ASMB] US$349 MM MCap
The mi­cro­biome pro­gram is de­vel­op­ing nov­el oral live mi­cro­bial bio­ther­a­peu­tic can­di­dates with As­sem­b­ly’s ful­ly in­te­grat­ed plat­form, in­clud­ing a ro­bust pro­cess for strain iden­ti­fi­ca­tion and se­lec­tion, GMP bank­ing and pro­duc­tion, and tar­get­ed de­liv­ery to the low­er gas­troin­testi­nal tract with the GEMI­CEL® tech­nol­o­gy. [more in­for­ma­tion]
Avacta [AVCT:LN] £31 MM MCap
Avac­ta is ad­dress­ing this need by com­bin­ing two pro­pri­e­tary plat­forms – Af­fimers®, a best-in-class anti­body mimet­ic and TMACTM, drug con­ju­gates that are ac­ti­vat­ed in the tu­mour mi­croen­vi­ron­ment to re­lease pro-in­flam­ma­to­ry drugs that syn­er­gise with the Af­fimer check­point mo­d­u­la­tors. [more in­for­ma­tion]
AxoGen [AXGN] US$769 MM MCap
Da­m­age or tran­sec­tion to pe­ripher­al nerves. Q1 revs $23.3M, 35% growth YoY; exp 2019 rev bt $109-$114M [more in­for­ma­tion]
Bavarian Nordic A/S [BVNRY] US$854 MM MCap
Vaccines for in­fec­tious dis­eas­es and on­col­o­gy. Can­cer vaccines in com­bo with mul­ti­ple check­point in­hibi­tors (Roche/Mer­ck/BMS). Uni­ver­sal RSV vaccine with pos­i­tive phase 2 da­ta. Re­cent con­tract from US Gov. for small­pox vaccine val­ued at over $500M. Part­n­er­ship with JNJ for vaccines against HIV/HBV/HPV with over $1B in po­ten­tial mile­s­tones. [more in­for­ma­tion]
Bellicum Pharmaceuticals Inc. [BLCM] US$80 MM MCap
Molec­u­lar switch tech­nol­o­gy and co-stim do­mains en­ables phar­ma­co­log­ic con­trol over cells for en­hanced ef­fi­ca­cy and safe­ty. Lead (reg­is­tra­tio­n­al EU) pro­gram: Ph2 for ri­vo-cel (al­pha/be­ta ad­d­back T-cell ther­a­py for post al­lo­gene­ic HSTC in non-ma­lig­nant and ma­lig­nant dis­eas­es). Pos­i­tive late in­ter­im anal­y­sis on ri­vo-cel exp at ASH 2018; [more in­for­ma­tion]
Bellus Health [BLU.CN]
Its pipe­line of pro­jects in­cludes the Com­pany’s lead drug can­di­date BLU-5937 for chron­ic cough and sev­er­al other part­nered clin­i­cal-stage drug de­vel­op­ment pro­grams. BLU-5937, a high­ly se­lec­tive P2X3 an­ta­g­on­ist, has the po­ten­tial to be a best-in-class ther­a­peu­tic for chron­ic cough pa­tients who do not re­spond to cur­rent ther­a­pies. [more in­for­ma­tion]
BerGenBio [BGBIO:OS] NKr775 MM MCap
De­vel­op­ing first-in-class se­lec­tive Axl ki­nase in­hibi­tors for liquid and solid can­cers, lead can­di­date is bem­cen­tinib (BG­B324) in four com­pany-spon­sored trials. [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$2,333 MM MCap
Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP re­cep­tor an­ta­g­on­ist and glu­ta­mate mo­d­u­la­tion plat­forms. In­ter­nal de­vel­op­ment and re­search with in­tel­lec­tu­al prop­er­ty li­censed from com­pa­nies and in­sti­tu­tions in­clud­ing BMS, As­traZene­ca, Yale Uni­ver­si­ty, Ca­ta­l­ent, ALS Bio­phar­ma and Mas­sachusetts Gen­er­al Hos­pi­tal. [more in­for­ma­tion]
BioPharmX [BPMX] US$5 MM MCap
De­vel­op­ing BPX-04 for rosacea, us­ing pro­pri­e­ta­ty hy­drophil­ic top­i­cal for­mu­la­tion tech­nol­o­gy. En­rolling Ph2b w da­ta exp in 2019. Com­plet­ed Ph 2b with BPX-01 in acne. [more in­for­ma­tion]
BioTime, Inc [BTX] US$177 MM MCap
Cell ther­a­py co de­vel­op­ing OpRe­gen in Ph 1/2 de­vel­op­ment for dry-AMD, OPC1 in Ph 1/2 de­vel­op­ment for spi­nal cord in­jury and VAC2 in Ph 1 de­vel­op­ment for NS­CLC. Al­so de­vel­op­ing Rene­via as a cell de­liv­ery plat­form for HIV lipoa­t­ro­phy (CE Mark re­sponse ex­pect­ed 2H19). Re­cent­ly ac­quired As­te­rias Bio­ther­a­peu­tics (AST), spun off AgeX (AGEX) and cur­rent­ly hold 28% of On­co­Cyte (OCX). [more in­for­ma­tion]
BlinkBio, Inc.
They have in­no­vat­ed a plat­form based on Tun­able Drug Con­ju­gate (TDCs) ther­a­pies used to di­rect­ly tar­get the de­liv­ery of toxins to tu­mors. The lead ther­a­peu­tic pro­gram tar­gets Fo­late Re­cep­tor al­pha and has been vali­dat­ed in the clin­ic by ADCs, pro­vid­ing a de-risked bench­mark for plat­form vali­da­tion and can­di­date de­vel­op­ment. [more in­for­ma­tion]
BrainStorm Cell Therapeutics Inc. [BCLI] US$94 MM MCap
NurOwn® au­tol­o­gous cell ther­a­py plat­form for neu­rode­gen­er­a­tive dis­eas­es. Lead can­di­date for ALS, Ph2 eval­u­at­ed 60 ALS pts w fa­vor­able safe­ty/tol­er­a­bil­i­ty. Ph3 cur­rent­ly en­rolling 200 pts across 6 US cen­ters; top-line da­ta ex­pect­ed in mid-2020. Phase 2 trial in pro­gres­sive MS on­go­ing at Cleve­land Clin­ic and Stan­ford Uni­ver­si­ty - to­p­line da­ta mid-2020. [more in­for­ma­tion]
CAI International, Inc. [CAI] US$430 MM MCap
CAI In­ter­na­tio­n­al Inc is a tran­s­por­ta­tion fi­nance and lo­gis­tics com­pany. It purchas­es equip­ment and then leas­es it to con­tain­er ship­ping lines, freight for­warders and other tran­s­por­ta­tion com­pa­nies. [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] US$306 MM MCap
Re­ceived MN­PA (f.k.a. CF­DA) ap­pro­val for EVOMELA® (mel­pha­lan for in­jec­tion: mul­ti­ple myelo­ma) on Dec 3, 2018; CF­DA re­view in progress for ZE­VALIN® and MAR­QI­BO® (in-li­censed from Spec­trum Phar­ma). Ac­qd 25 US FDA-ap­proved AN­DAS from San­doz in Jan 2018. [more in­for­ma­tion]
Catalyst Pharmaceuticals, Inc. [CPRX] US$422 MM MCap
Fir­dapse ap­proved 11/18, Q1 sales of $12m: 380 ac­tive LEMS pa­tients on ther­a­py (a/o May 9) [more in­for­ma­tion]
Cellular Biomedicine Group, Inc. [CBMG] US$270 MM MCap
This vali­dates CB­MG's in-house cell man­u­fac­tur­ing ca­pa­bil­i­ties de­vel­oped in part­n­er­ship with Gen­er­al Elec­tric and Ther­mo Fish­er. CB­MG's pro­pri­e­tary im­muno-on­col­o­gy pipe­line in­cludes BC­MA, CD22, TCR-T for HCC and TIL for the treat­ment of NS­CLC and other solid tu­mors. [more in­for­ma­tion]
CureVac AG
Found­ing Co of mR­NA space (last round $1bn+). In­tra­tu­mo­ral ther­a­py Ph1 (mul­ti­ple onc in­di­ca­tions) ini­ti­at­ed Q4 17, ear­ly da­ta rep at SITC. First pt en­rolled Ph 1 pro­phy­lac­tic mR­NA ra­bies vax Oct 2018. Pro­phy­lac­tic in­fluen­za vax ini­ti­a­tion Ph 1 2020, OTC de­fi­cien­cy Ph 1 ini­ti­a­tion H219. In­ter­im da­ta /all trials: 2019. [more in­for­ma­tion]
Enzo Biochem, Inc. [ENZ] US$178 MM MCap
$100m revs in F18. Pi­oneer in molec­u­lar di­ag­nos­tics (Dx), lead­ing con­ver­gence of clin­i­cal lab­o­ra­to­ries, life sci­ences and IP through de­vt of unique Dx plat­form tech­nolo­gies pro­vid­ing nu­mer­ous ad­van­tages over pre­vi­ous stan­dards. [more in­for­ma­tion]
ESSA Pharma Inc. [EPIX] US$15 MM MCap
Sm molecule drugs: cas­tra­tion-re­sis­tant pros­tate can­cer. EPI-506, exp to en­ter clin­ic YE19 (se­cond-gen com­pound). De­vel­op­ing com­pounds bind­ing to N-ter­mi­nus of AR and block sig­nal­ing. MOA po­ten­tial­ly over­comes re­sis­tance mech­anisms cur­rent­ly seen in me­tastat­ic pros­tate can­cer. [more in­for­ma­tion]
Evofem Biosciences, Inc. [EVFM] US$220 MM MCap
Se­cured $30M strate­g­ic in­vest­ment from PDL Bio­S­ciences (PDLI) in April 2019 for 6.7M shares at $4.50 (26% pre­mi­um to pri­or day close) and 25% war­rant cov­er­age. [more in­for­ma­tion]
Forbius
Se­lec­tive in­hibi­tors of TGF Be­ta & EGFR path­ways. AACR: (+) Ph 1 da­ta. 3 on­go­ing Ph 2 trials (SCCHN, NS­CLC, TN­BC); ad­dl Ph 1 trials in IO, Sys­temic Scle­ro­sis & Myelo­fi­bro­sis [more in­for­ma­tion]
Genfit SA [GNFTF] US$758 MM MCap
$155m Mar 2019 US IPO; FDA BTD for Ela­fi­branor (4/19); (+) 36-mo DSMB rec for cont­in­u­a­tion of Ph 3 study in NASH; da­ta by YE [more in­for­ma­tion]
GenSight Biologics [SIGHT:PA] €49 MM MCap
Gene ther­a­py: reti­nal & CNS de­gen­er­a­tive patholo­gies and mi­to­chon­drial dis­ease. Fil­ing for MAA exp Q4 2019 in EU and 2020 in US. Op­to­ge­net­ic pro­gram and tar­get­ed dis­ease im­me­di­ate­ly trans­fer­able to dry AMD. Plat­form com­bines mono-ge­net­ic ther­a­py-based ap­proach w core tech­nol­o­gy plat­form and pro­pri­e­tary Mi­to­chon­drial Tar­get­ing Se­quence. [more in­for­ma­tion]
HaemaLogiX
I-O; nov­el tgts in Mul­ti­ple Myelo­ma (col­lab w Take­da). Kap­paMab (MM) Ph 2b, da­ta 1H20. Kap­paMab Car-T en­ter­ing clin­ic 2019. Kap­paMab & Lamb­daMab tar­get cell sur­face pro­teins KMA and LMA on ab­nor­mal plas­ma cells. Kap­paMab: com­plete & par­tial re­spons­es in Ph 1 & 2a. Kap­pa-mab Car-T en­ter­ing clin­ic 2019. [more in­for­ma­tion]
Hutchison China MediTech Ltd ("Chi-Med") [HCM] US$2,925 MM MCap
It has a port­fo­lio of eight can­cer drug can­di­dates cur­rent­ly in late stage clin­i­cal studies around the world. In Novem­ber 2018, fruquin­tinib (Elu­nate) was com­mer­cial­ly launched in Chi­na for the treat­ment of pa­tients with me­tastat­ic col­orec­tal can­cer (CRC). [more in­for­ma­tion]
Idera Pharmaceuticals, Inc. [IDRA] US$73 MM MCap
Lead can­di­date Til­so­toli­mod (TLR 9 ag­on­ist) used in comb w Ipi in PD1 re­frac­to­ry me­lano­ma pts. En­rolling ad­dl pts in Ph 2 ex­pan­sion and Phase 3 en­roll­ment ex­pect­ed to com­plete Q4 2019. Com­bo of ipi and Til­so­toli­mod ap­pears to ac­ti­vate im­mune re­sponse in pts who have ex­haust­ed all op­tions, e.g. PD1/CPIs. Fast Track des for Til­so­toli­mod (Nov’17). [more in­for­ma­tion]
Inspirion Delivery Sciences LLC
Mor­phaBond ER™ US com­mer­cial launch Nov 2017 (FDA-ap­proved, first sin­gle-en­ti­ty abuse de­ter­rent ER mor­phine prod­uct) and Rox­y­Bond™ (FDA ap­proved, first and on­ly IR abuse-de­ter­rent opi­oid prod­uct) both li­censed to Daiichi Sankyo, Inc. Nov­el ex­tend­ed and im­me­di­ate re­lease tech­nolo­gies en­able pain med­i­ca­tions with abuse de­ter­rent fea­tures, ad­dress­ing the Opi­oid epi­dem­ic. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] US$3,068 MM MCap
Late-stage cell ther­a­py com­pany uti­l­iz­ing pro­pri­e­tary au­tol­o­gous tu­mor in­fil­trat­ing lym­pho­cytes (TILs) to at­tack solid tu­mors. The com­pany is con­duct­ing piv­o­tal stage trial in me­tastat­ic me­lano­ma and will define reg­u­la­to­ry path in ad­vanced cer­vi­cal can­cer mid-year 2019, with break­through ther­a­py desig­na­tion award­ed in May 2019. [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$329 MM MCap
Plat­form of ROCK in­hibi­tors. ROCK2 in­hibi­tor in reg­is­tra­tion trial cGVHD; en­roll­ment com­ple­tion exp 2H19; ini­tial anal­y­sis exp YE. Ph 2 ini­ti­a­tion in scle­ro­der­ma exp in 2019. [more in­for­ma­tion]
Kineta
Kine­ta (Pri­vate) is fo­cused on in­nate im­mu­ni­ty and im­munol­o­gy. Signed 2 large ear­ly stage part­ner­ing deals in 2018 - $520M deal with Pfiz­er for its small molecule RIG-I im­munother­a­py and a $360M+ deal with Ge­nen­tech for KCP506, a pre­clin­i­cal, non-opi­oid for chron­ic pain. LHF-535 in Ph 1 for Las­sa Fev­er (fund­ed by Well­come Trust, eli­gi­ble for PRV). [more in­for­ma­tion]
Marker Therapeutics [MRKR] US$409 MM MCap
A clin­i­cal-stage im­muno-on­col­o­gy com­pany with the po­ten­tial to sig­ni­f­i­cant­ly dis­rupt the cur­rent cell ther­a­py land­s­cape. Mark­er's cur­rent Mul­ti­TAA cell ther­a­py is look­ing to ini­ti­ate a Phase II study in AML in 2019. Ad­di­tio­n­al­ly, TPIV200, a T-cell vaccine is cur­rent­ly in Phase 2 for ovarian can­cer and tri­ple-neg­a­tive breast can­cer. [more in­for­ma­tion]
Medigene AG [MDG1:DB] €171 MM MCap
blue­bird bio col­lab; BLUE ini­ti­at­ing trial w/MDG MAGEA-4 can­di­date in 2020. TCRs tar­get­ing HA-1 & MAGE-A1 in de­vt. . DC vax in on­go­ing Ph 1/2; fi­nal read­out in 2019. [more in­for­ma­tion]
Medivir AB [MVIR B:ST] SKr936 MM MCap
Me­di­vir is a phar­ma­ceu­ti­cal com­pany fo­cus­ing on the de­vel­op­ment and com­mer­cial­iza­tion of in­no­va­tive treat­ments for can­cer. To do this ef­fi­cient­ly and with a high suc­cess rate, Me­di­vir brings to­gether a unique com­bi­na­tion of clin­i­cal de­vel­op­ment skills, a col­lab­o­ra­tive cul­ture and an ex­ten­sive in­dus­try ex­pe­ri­ence, with a bal­anced pro­ject port­fo­lio. [more in­for­ma­tion]
Minerva Neurosciences, Inc. [NERV] US$249 MM MCap
Ph 3 tar­get­ing neg symp­toms as­soc w/ schi­zophre­nia; to­p­line re­sults exp 4Q19. 3 Ph 2b trials on­go­ing w/Janssen MDD/in­som­nia. (+) to­p­line Ph 2 b da­ta w/20mg dose; in­som­nia read­out exp 2Q19 [more in­for­ma­tion]
NeuroRx
De­vel­op­ing first Glx tar­get­ed an­tide­pres­sant to ad­dress sui­ci­dal­i­ty in bipo­lar de­pres­sion. Lead can­di­date, NRX-101 in Ph 2b/3 de­vt (Break­thru Desig­na­tion, SPA and Fast Track Desig­na­tion by FDA) for Se­vere Bipo­lar De­pres­sion in pts w Acute Sui­ci­dal Idea­tion and Be­havior. Plans to pre­sent Ph 2 POC da­ta lat­er this year. [more in­for­ma­tion]
NexImmune, Inc.
Anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Mul­ti­ple IND fil­ings exp H1'19. [more in­for­ma­tion]
Oncimmune [ONC:LN] £63 MM MCap
Oncim­mune's pro­pri­e­tary plat­form is un­der­pinned by rapid bio­mark­er dis­cov­ery and a com­pre­hen­sive im­muno­genic pro­tein li­brary of over 8,000 anti­genic pro­teins. [more in­for­ma­tion]
Oncopeptides AB [ONCO:ST] SKr8,326 MM MCap
Melflufen (Yga­lo): alky­lat­ing pep­tide se­lec­tive­ly tar­gets MM; su­pe­ri­or ef­fi­ca­cy vs. SOC. In­ter­im da­ta at EHA (2018) from on­go­ing Ph2 study in late stage r/r MM showed ORR of ~32%. [more in­for­ma­tion]
PAION AG [PAIOF] US$163 MM MCap
Remi­ma­zo­lam: short-act­ing anes­thet­ic. Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US ap­pro­val filed by part­n­er Cos­mo Phar­ma­ceu­ti­cals in June 2019. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2019. [more in­for­ma­tion]
PharmaMar SA [PHM:ES]
2018 to­tal rev­enues of &eu­ro;162M. Yon­delis (soft tis­sue sar­co­ma and ovarian can­cer) com­mer­cial­ized w di­rect sales-force in EU and part­n­er­ship in US w Janssen. Zep­syre in Ph 3 trials for SCLC - da­ta due 2H19. MOA: Op­ti­mized ana­log of Yon­delis. [more in­for­ma­tion]
Pharming Group NV [PHARM:AS] €503 MM MCap
On­ly prod­uct with fu­ture po­ten­tial to be ap­proved for both pro­phy­laxis and treat­ment of at­tacks of HAE. An­nounced pos­i­tive re­sults from a ph2 study of RU­CON­EST in Con­tract-in­duced Nephro­pa­thy for pa­tients re­ceiv­ing elec­tive coro­nary an­giog­ra­phy with or with­out a per­cu­ta­neous coro­nary in­ter­ven­tion (PCI). [more in­for­ma­tion]
Pharvaris
Phar­varis is a pre­clin­i­cal stage com­pany fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and other B2 re­cep­tor-me­di­at­ed in­di­ca­tions. POC was de­mon­s­trat­ed in a mon­key mod­el and it’s ap­pli­ca­ble to all pa­tients in HAE. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$222 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Pliant Therapeutics, Inc.
Lead pro­gram is a small molecule du­al se­lec­tive in­hibi­tor of avb6/avb1 in­te­grins for IPF, pri­mary scle­ros­ing cholan­gi­tis (PSC), and re­nal fi­bro­sis - re­ceived or­phan drug desig­na­tion and will en­ter Ph1 in De­cem­ber 2018. Se­cond pro­gram is a se­lec­tive avb1 in­hibi­tor for the treat­ment of end stage liv­er fi­bro­sis and has en­tered in­to de­vel­op­ment can­di­date se­lec­tion. [more in­for­ma­tion]
Portage Biotech [PTGEF] US$102 MM MCap
Por­tage choos­es prod­ucts with estab­lished sci­en­tif­ic ra­tio­nales and ei­ther cre­ates ma­n­age­ment teams to de­vel­op th­ese as­sets or aug­ments a com­pany’s ex­ist­ing ma­n­age­ment teams. Por­tage cre­ates much of its val­ue by de­vel­op­ing pre-proof of con­cept as­sets through proof of con­cept (POC). [more in­for­ma­tion]
Protagonist Therapeutics [PTGX] US$309 MM MCap
PTG-300, in­jectable hep­cidin mimet­ic in Ph 2 Be­ta-Tha­lassemia study with ini­tial re­sults ex­pect­ed 2H19. PTG-200, part­nered w Janssen, oral GI-re­strict­ed IL-23R an­ta­g­on­ist for Crohn’s dis­ease com­plet­ed Ph 1 in Novem­ber 2018. PN-943, oral GI-re­strict­ed al­pha4­be­ta7 in­te­grin-spe­cif­ic an­ta­g­on­ist in UC in Ph 1, with mul­ti­ple as­cend­ing dose re­sults ex­pect­ed 3Q19. [more in­for­ma­tion]
Protalix BioTherapeutics [PLX] US$61 MM MCap
Lead as­set in mul­ti Ph 3 trials for Fab­ry dis­ease, part­nered glob­al­ly w Chie­si - In­ter­im Ph 3 (PRX-102) da­ta: im­prove­ment in kid­ney func­tion in pts switched from Re­pla­gal®. Ad­dl Ph 2 (in Cys­tic Fi­bro­sis) [more in­for­ma­tion]
Pulse Biosciences, Inc. [PLSE] US$256 MM MCap
Med de­vice: Nano-Pulse Elec­tro-Sig­nal­ing [more in­for­ma­tion]
R2 Dermatology
Di­rec­tor of the Well­man Cen­ter of Pho­tomedicine at Mas­sachusetts Gen­er­al Hos­pi­tal in Bos­ton, a teach­ing af­fili­ate of Har­vard Med­i­cal School; of the Cu­ta­neous Bi­ol­o­gy Re­search Cen­ter in the De­part­ment of Der­ma­tol­o­gy at Mas­sachusetts Gen­er­al Hos­pi­tal; [more in­for­ma­tion]
Regent Pacific [575:HK]
Re­gent Pa­cif­ic is a di­ver­si­fied in­vest­ment group based in Hong Kong cur­rent­ly hold­ing vari­ous cor­po­rate and strate­g­ic in­vest­ments fo­cus­ing on the health­care, well­ness and life sci­ences sec­tors. The Group has a strong track re­cord of in­vest­ments and has re­turned ap­prox­i­mate­ly US$298 mil­lion to share­hold­ers in the 21 years of fi­nan­cial re­port­ing since its ini­tial public of­fer­ing. [more in­for­ma­tion]
Resolve Therapeutics
The com­pany has lev­er­aged re­cent sci­en­tif­ic ad­vances to de­vel­op new, high­ly tar­get­ed, safer ther­a­pies for th­ese dis­eas­es, and is at the fore­front of pi­oneer­ing a com­plete­ly new ap­proach to treat­ing Lu­pus and Sjögren’s syn­drome. [more in­for­ma­tion]
Savara Inc. [SVRA] US$95 MM MCap
Or­phan lung dis­ease; Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion [more in­for­ma­tion]
Selvita S.A
PIM/FLT3 ki­nase in­hibi­tor in Ph 1/2 in AML (part­nered w Me­nari­ni) and sm molecule se­lec­tive CD­K8 in­hibi­tor for leukemias, lym­pho­mas, and solid tu­mors: Ph 1/2 ini­ti­a­tion exp H1 2019 [more in­for­ma­tion]
Sernova [SEOVF] US$29 MM MCap
Ser­no­va Corp. is a clin­i­cal-stage re­gen­er­a­tive medicine com­pany com­mer­cial­iz­ing prod­ucts which ben­e­fit pa­tients with chron­ic metabolic, neu­ro­log­i­cal and he­ma­to­log­i­cal dis­eas­es with first ther­a­peu­tic ap­pli­ca­tions in di­a­betes and he­mophilia. The com­pany is cur­rent­ly con­duct­ing a PI/II trial in di­a­bet­ic pa­tients with Hy­po­g­lycemia un­aware­ness. [more in­for­ma­tion]
Sol-Gel Technologies Ltd. [SLGL] US$191 MM MCap
Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). 2 P3 read­outs in 2019: Rosacea: mid-2019; Acne: YE [more in­for­ma­tion]
Sonnet Biotherapeutics, Inc.
[more in­for­ma­tion]
Stemline Therapeutics, Inc. [STML] US$568 MM MCap
EL­ZON­RIS, tar­get­ed ther­a­py di­rect­ed to IL-3 re­cep­tor (CD123, ap­proved for BPDC; SL-801 an oral small molecule re­v­ersi­ble in­hibi­tor of XPO1 in Ph 1 trial; and SL-701 an im­munother­a­peu­tic that com­plet­ed Ph 2 trial in pts w/2nd line GBM [more in­for­ma­tion]
STRATEC Biomedical AG [SBS:FF] €641 MM MCap
Au­to­ma­tion sys­tems and soft­ware for di­ag­nos­tics in­dus­try. In­s­talled base of >13,000 sys­tems across 20 fam­i­lies in­clud­ing PAN­THER (Ho­log­ic), Li­a­son XL (Di­a­Sorin), VI­DAS (BioMerieux) and AD­VIA (Sie­mens). Rev gen­er­at­ing and pro­f­itable; growth drivers in­cl prod­uct launch­es/ramp-ups, new tests; de­mo­graph­ics and out­sourc­ing in IVD in­dus­try. [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$150 MM MCap
Rare dis­eas­es; Keveyis for PPP 2019 rev­enue gui­dance of $18-20M; Re­cor­lev 2nd Phase 3 top-line re­sults 1Q 2020; NDA sub­mis­sion exp 3Q 2020 [more in­for­ma­tion]
Sutro Biopharma [STRO] US$261 MM MCap
Fo­cused on de­vel­op­ing next gen­er­a­tion anti­body drug con­ju­gates (ADCs) and mul­ti-spe­cif­ic anti­body-based ther­a­peu­tics for can­cer ther­a­py. STRO-001 for mul­ti­ple myelo­ma and lym­pho­mas is in Ph 1 and ex­pects ini­tial safe­ty da­ta in mid-2019. IND sub­mis­sion for STRO-002 for ovarian and en­dome­trial can­cer in Q4 2018 with the ini­ti­a­tion of a Ph 1 trial planned for ear­ly 2019. [more in­for­ma­tion]
Syneos Health [SYNH] US$5,056 MM MCap
On­ly ful­ly in­te­grat­ed bio­phar­ma­ceu­ti­cal so­lu­tions or­gani­za­tion in­cl CRO and Con­tract Com­mer­cial Or­gani­za­tion (CCO)/ (merg­er of INC Re­search & in­Ven­tiv) [more in­for­ma­tion]
Taiwan Liposome Company [TLC] US$166 MM MCap
TLC is a clin­i­cal-stage spe­cial­ty phar­ma­ceu­ti­cal com­pany ded­i­cat­ed to the de­vel­op­ment and com­mer­cial­iza­tion of nov­el nanomedicines that com­bine pro­pri­e­tary lipid-as­sem­bled drug de­liv­ery plat­forms with ap­proved ac­tive phar­ma­ceu­ti­cal in­gre­di­ents (APIs). All pro­grams ex­pect­ed to be in late or piv­o­tal stage by the end of 2020. [more in­for­ma­tion]
Targovax [TRVX:OS] NKr428 MM MCap
Tar­go­v­ax is a clin­i­cal stage biotech­nol­o­gy com­pany de­vel­op­ing im­mune ac­ti­va­tors to tar­get hard-to-treat solid tu­mors. Tar­go­v­ax’s lead prod­uct can­di­date, ON­COS-102, is a ge­net­i­cal­ly mod­i­fied on­co­lyt­ic ade­n­ovirus that has been en­gi­neered to se­lec­tive­ly in­fect and re­pli­cate in can­cer cells. It has been shown to ac­ti­vate the im­mune sys­tem to gen­er­ate tu­mor-spe­cif­ic im­mune re­spons­es. [more in­for­ma­tion]
Tessa Therapeutics
On­go­ing Ph III – (na­sopha­ryn­geal can­cer), Ph I – (cer­vi­cal, mov­ing in­to Ph II); mul­ti­ple other as­sets en­ter­ing clin­ic. Key col­labs: Bay­lor, Park­er Inst, St. Jude Chil­dren’s [more in­for­ma­tion]
Trio Health
Strives to col­lect and an­a­lyze re­al world evi­dence that may be used to im­prove the qual­i­ty of health care avai­l­able to all pa­tients. Trio has de­vel­oped a pro­pri­e­tary tech­nol­o­gy plat­form that re­defines the ap­proach and metho­d­ol­o­gy of col­lect­ing ret­ro­spec­tive ob­ser­va­tio­n­al da­ta on re­al world pa­tients. [more in­for­ma­tion]
Valbiotis [AVAL-FR]
De­vel­op­ing pro­pri­e­tary plant-de­rived bio­molecules to pre­vent metabolic dis­eas­es. Lead pro­gram VALE­DIA®, tar­get­ing the un­ad­dressed pre­di­a­betes mar­ket, re­cent­ly re­port­ed pos­i­tive Ph 2a da­ta for pre­di­a­betes. VALE­DIA® sig­ni­f­i­cant­ly re­duced fast­ing blood glu­cose lev­els, com­pared to the place­bo, af­ter 6 months (p [more in­for­ma­tion]
Vericel Corporation [VCEL] US$854 MM MCap
Ad­vanced cell ther­a­py; mar­ket­ing MA­CI (car­ti­lage re­pair) and Epi­cel (skin re­place­mentt) in TAMs of $2b+. Re­cent­ly ac­quired US com­mer­cial rights for Nexo­Brid. [more in­for­ma­tion]
Viela Bio
Lead pro­gram, Ine­bi­l­izumab, is a CD19 mAb which met the pri­mary end­point in the Ph 2b piv­o­tal study for the treat­ment of Neu­romyeli­tis Op­ti­ca. Pri­mary anal­y­sis de­mon­s­trat­ed a 77% re­duc­tion in the risk of de­vel­op­ing NMOSD at­tack in pa­tients treat­ed with ine­bi­l­izumab monother­a­py com­pared to place­bo. [more in­for­ma­tion]
vTv Therapeutics, Inc. [VTVT] US$84 MM MCap
June 2019 pos­i­tive da­ta for TT­P399 as an add-on ther­a­py to in­sulin ther­a­py in a 12 week phase 1/2 trial in pa­tients with T1D. Re­sults from a sub­group anal­y­sis of the STEAD­FAST Alzheimer’s trial pre­sent­ed at CTAD - mov­ing Azeli­ra­gon for­ward in pa­tients with De­men­tia and Di­a­betes. [more in­for­ma­tion]
Yisheng Biopharma
Prod­ucts in de­vt in­clude YS-ON-001 (Ph 1), an IO prod­uct tar­get­ing solid tu­mors and new gen of bi­o­log­ics for pre­ven­tive and ther­a­peu­tic ben­e­fits, in­cl YS-HBV-001 (Ph 1) and PI­KA ra­bies vaccine (Ph 3), tar­get­ing hep B and ra­bies in­fec­tions. PC pro­grams in­cl bi­o­log­ics tar­get­ing in­fluen­za, her­pes zoster, ebo­la, et al. 2 bi­o­log­ics prod­ucts on mkt. [more in­for­ma­tion]